TY  - JOUR
T1  - Evaluation of Botulinum Toxin Applications in a  Tertiary Cosmetic Department
TT  - Bir Eğitim Araştırma Hastanesinde Kozmetik Amaçlı Botulinum Toksin Uygulamalarının Değerlendirilmesi
AU  - Örenay, Özge Mine
AU  - Temel, Berkay
AU  - Karaosmanoğlu, Nermin
PY  - 2024
DA  - January
DO  - 10.20492/aeahtd.1278151
JF  - Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
PB  - Sağlık Bakanlığı Ankara Eğitim ve Araştırma Hastanesi
WT  - DergiPark
SN  - 1304-6187
SP  - 156
EP  - 159
VL  - 56
IS  - 3
LA  - en
AB  - Aim: Botulinum toxin type A (BTX-A) treatment for facial rejuvenation hasbeen started to used widely and become the most common aesthetic procedure. The aim inthis study to evaluate the patients features and outcomes who had Onabotulinumtoxin A.Material and Method: The data of the BTX-A patient’s gender, age, occupation, history of cosmeticprocedures, history of disease, doses of the first and control injections, complications andexpectations from the therapy collected from the medical records. The patients were dividedinto two groups as under the age of 45 and age of 45 and older. These groups were comparedwith each other in terms of mentioned variables.Results: A total of 200 patients included in this study. The mean botulinum toxin dose was33.7 units and the mean control dose was 4.5 units. Three (1.5%) of the patients developed acomplication, all of them were eyelid ptosis. Most common expectation from the toxininjection was to look more young (69%) and vigorous (75.5%). There were no significantdifference between the under the age of 45 and 45 and older group in terms of total BTX-Adose and control dose and complication rate (p=0.8, p=0.5, p=0.6). Expectation of lookingless angry and less saggy were significantly higher in the 45 year and older group (p=0.02,p=0.02).Conclusion: It is important to evaluate the patient’s gender, age and expectations from thebotulinum toxin injection to get the highest efficiency from BTX-A injection.
KW  - botox
KW  - wrinkles
KW  - face rejunevation
N2  - GİRİŞ-AMAÇ: Botulinum toksini, Gram negatif bir bakteri olan Clostridium botulinum tarafından sentezlenenbir nörotoksindir. Kozmetik amaçlı ilk kez 1992 yılında glabella kırışıklıkları tedavisinde kullanılmıştır. Fasiyalkırışıklık tedavisinde giderek artan sıklıklarla uygulanmaya başlanmıştır. Bu çalışmada, eğitim araştırmahastanesinde kozmetik amaçlı uygulanan botulinum toksin uygulamalarının değerlendirilmesini amaçladık.YÖNTEM: Çalışmaya, 2018-2019 yıllarında hastanemizin kozmetoloji ünitesine kozmetik amaçlı botulinumtoksin uygulaması için başvurmuş 200 hasta dahil edilmiştir. Hastaların dosyaları taranarak; demografikbulguları, kozmetik işlem geçmişleri, uygulanan botoks dozları, kontrol dozu uygulamaları, komplikasyonlar vebotokstan beklentileri kaydedildi. Ayrıca hastalar 45 yaş altı ve 45 yaş ve üstü olarak iki gruba ayrılarak, ikigrubun kozmetik işlem geçmişleri, uygulanan botoks dozları, kontrol dozu uygulamaları, komplikasyonlar vebotokstan beklentileri karşılaştırılmıştır.BULGULAR: Çalışmaya dahil edilen 200 hastanın 195’i kadın (%97,5) ve 5’i erkek (%2,5) hastaydı. Hastalarınyaş ortalaması 44,8 idi. Daha önce hastaların 107’si (%53,5) botoks yaptırmış, 40’ı (%20) ise dolgu işlemiyaptırmıştır. Hastaların hepsine üst yüz botoksu uygulanırken, alt yüz botoksu 55 (%27,5) hastaya uygulandı.Hastalara uygulanan total botoks dozu 33,7 Ü idi. Hastaların 131’ine (%65,5) kontrol doz uygulandı. Uygulanankontrol doz ortalaması 4,5 Ü idi. Hastaların 3’ünde (%1,5) komplikasyon olarak pitozis gözlendi. Hastalar dinçgörünme, mutlu görünme, çekici görünme, zarif görünme, feminen görünme, genç görünme, az öfkeli görünmeve az sarkık görünme seçenekleri arasından, en çok dinç görünmek için botoks yaptırdığını belirtmiştir. Kırkbeşyaş altı hasta grubunda 101 kadın ve 3 erkek (total:104), 45 yaş ve üstü grubunda 94 kadın ve 2 erkek (total:96)vardı. Hastalar 45 yaş altı ve 45 yaş ve üstü olarak karşılaştırıldığında; botoks ve dolgu geçmişi, alt yüz botoksişlemi, total ve kontrol doz ortalaması, komplikasyon gelişimi açısından istatiksel olarak anlamlı farksaptanmamıştır. Hastaların botoks işleminden beklentisine bakıldığında ise 45 yaş ve üstü grubun, 45 yaş altıgruba göre daha az öfkeli ve daha az sarkık görünme isteği anlamlı yüksek bulunmuştur (p=0,018, p=0,029).SONUÇ: Botoks tedavisi hastaların farklı amaçlarla başvurduğu, kişi bazlı değerlendirme gerektiren etkili vekomplikasyon oranı düşük bir tedavi yöntemidir.
CR  - 1.Jia Z, Lu H, Yang X, Jin X, Wu R, Zhao J, et al. Adverse Events of
Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review
and Meta-Analysis. Aesthetic Plast Surg. 2016;40(5):769-77.
CR  - 2.Charles FJ, Cox SE, Earl ML. Social implications of hyperfunctional
facial lines. Dermatol Surg. 2003;29(5):450-5.
CR  - 3.Gart MS, Gutowski KA. Overview of Botulinum Toxins for Aesthetic
Uses. Clin Plast Surg. 2016;43(3):459-71.
CR  - 4.American Society of Plastic Surgeons. 2018 National PlasticSurgery
Statistics; 2018. www.plast icsur gery.org/documents/News/Statistics/
2018/plastic-surge ry-stati stics-report-2018.pdf.Accessed
June 28, 2019.
CR  - 5.Niamtu J 3rd. Complications in fillers and Botox. Oral Maxillofac Surg
Clin North Am. 2009;21(1):13-21, v. doi: 10.1016/j.coms.2008.11.001.
PMID: 19185791.
CR  - 6.Casabona G, Kaye K, Barreto Marchese P, Boggio R, Cotofana S. Six
years of experience using an advanced algorithm for botulinum toxin
application. J Cosmet Dermatol. 2019;18(1):21-35.
CR  - 7.Carruthers A, Bogle M, Carruthers JD, Dover JS, Arndt KA, Hsu TS,
et al. A randomized, evaluator-blinded, two-center study of the safety
and effect of volume on the diffusion and efficacy of botulinum toxin
type A in the treatment of lateral orbital rhytides. Dermatol Surg.
2007;33(5):567-71.
CR  - 8.Carruthers A, Bruce S, Cox SE, Kane MA, Lee E, Gallagher CJ. OnabotulinumtoxinA
for Treatment of Moderate to Severe Crow’s Feet
Lines: A Review. Aesthet Surg J. 2016;36(5):591-7.
CR  - 9.Gangigatti R, Bennani V, Aarts J, Choi J, Brunton P. Efficacy and
safety of Botulinum toxin A for improving esthetics in facial complex:
A systematic review. Braz Dent J. 2021;32(4):31-44.
CR  - 10.American Society for Aesthetic Plastic Surgery. 15th AnnualCosmetic
Surgery National Data Bank Statistics. 2011 Statistics
CR  - 11.D’Emilio R, Rosati G. Full-face treatment with onabotulinumtoxinA:
Results from a single-center study. J Cosmet Dermatol.
2020;19(4):809-816.
CR  - 12.Sepehr A, Chauhan N, Alexander AJ, Adamson PA. Botulinum toxin
type a for facial rejuvenation: treatment evolution and patient satisfaction.
Aesthetic Plast Surg. 2010;34(5):583-6.
CR  - 13.Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group.
Consensus recommendations on the use of botulinum toxin type a
in facial aesthetics. Plast Reconstr Surg. 2004;114(6 Suppl):1S-22S.
CR  - 14.Carruthers JDA, Glogau RG, Blitzer A; Facial Aesthetics Consensus
Group Faculty. Advances in facial rejuvenation: botulinum toxin type a,
hyaluronic acid dermal fillers, and combination therapies--consensus
recommendations. Plast Reconstr Surg. 2008;121(5 Suppl):5S-30S.
CR  - 15.Ahn BK, Kim YS, Kim HJ, Rho NK, Kim HS. Consensus recommendations
on the aesthetic usage of botulinum toxin type A in Asians.
Dermatol Surg. 2013;39(12):1843-60.
CR  - 16.Sommer B, Bergfeld D, Sattler G. Consensus recommendations on
the use of botulinum toxin type A in aesthetic medicine. J Dtsch Dermatol
Ges. 2007;5(1):S1-S29.
CR  - 17.Carruthers A, Carruthers J. Prospective, double-blind, randomized,
parallel-group, dose-ranging study of botulinum toxin type A in men
with glabellar rhytids. Dermatol Surg. 2005;31(10):1297-303.
CR  - 18.Sharova AA. Comparison of different consensuses of BTXA in different
countries. J Cosmet Dermatol. 2016;15(4):540-548.
CR  - 19.D’Emilio R, Rosati G. Full-face treatment with onabotulinumtoxinA:
Results from a single-center study. J Cosmet Dermatol.
2020;19(4):809-816.
CR  - 20.Kim BW, Park GH, Yun WJ, Rho NK, Jang KA, Won CH, et al. Adverse
events associated with botulinum toxin injection: a multidepartment,
retrospective study of 5310 treatments administered to 1819
patients. J Dermatolog Treat. 2014;25(4):331-6.
CR  - 21.Zargaran D, Zoller F, Zargaran A, Rahman E, Woollard A, Weyrich T,
et al. Complications of Cosmetic Botulinum Toxin A Injections to the
159
Upper Face: A Systematic Review and Meta-Analysis. Aesthet Surg
J. 2022;42(5):NP327-NP336.
CR  - 22.Sethi N, Singh S, DeBoulle K, Rahman E. A Review of Complications
Due to the Use of Botulinum Toxin A for Cosmetic Indications.
Aesthetic Plast Surg. 2021;45(3):1210-1220.
CR  - 23.Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini
J. A multicenter, randomized, double-blind, placebo-controlled
study of efficacy and safety of 3 doses of botulinum toxin A in the
treatment of glabellar lines. J Am Acad Dermatol. 2004;51(2):223-
33.
CR  - 24.Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind,
randomized comparison of 3 doses of botulinum toxin type A
and placebo in patients with crow’s feet. J Am Acad Dermatol.
2002;47(6):834-40.
CR  - 25.Solish N, Rivers JK, Humphrey S, Muhn C, Somogyi C, Lei X, et al.
Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead
Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
Dermatol Surg. 2016;42(3):410-9.
CR  - 26.Sundaram H, Signorini M, Liew S, Trindade de Almeida AR, Wu
Y, Vieira Braz A, et al; Global Aesthetics Consensus Group. Global
Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based
Review, Emerging Concepts, and Consensus Recommendations for
Aesthetic Use, Including Updates on Complications. Plast Reconstr
Surg. 2016;137(3):518e-529e.
CR  - 27.Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; Botox Glabellar
Lines II Study Group. Double-blind, placebo-controlled study
of the safety and efficacy of botulinum toxin type A for patients with
glabellar lines. Plast Reconstr Surg. 2003;112(4):1089-98.
CR  - 28.Yeslev M, Gupta V, Winocour J, Shack RB, Grotting JC, Higdon
KK. Safety of Cosmetic Procedures in Elderly and Octogenarian Patients.
Aesthet Surg J. 2015;35(7):864-73.
UR  - https://doi.org/10.20492/aeahtd.1278151
L1  - http://dergipark.org.tr/tr/download/article-file/3063807
ER  -